Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.
作者信息
Giuliani Jacopo, Bonetti Andrea
机构信息
Department of Oncology, Mater Salutis Hospital-ASL 21 della Regione Veneto, Legnago (VR), Italy.
出版信息
Chin J Cancer Res. 2013 Oct;25(5):486-7. doi: 10.3978/j.issn.1000-9604.2013.10.13.
Abstract
摘要
相似文献
1
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate.
Chin J Cancer Res. 2013 Oct;25(5):486-7. doi: 10.3978/j.issn.1000-9604.2013.10.13.
2
Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.
Tumori. 2010 May-Jun;96(3):392-9. doi: 10.1177/030089161009600303.
3
Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report.
J Med Case Rep. 2011 May 21;5:197. doi: 10.1186/1752-1947-5-197.
4
Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.
J Natl Med Assoc. 2003 Dec;95(12):1208-10.
5
Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
Langenbecks Arch Surg. 2006 Nov;391(6):615-21. doi: 10.1007/s00423-006-0103-z. Epub 2006 Oct 6.
6
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
Jpn J Clin Oncol. 2012 Jul;42(7):578-85. doi: 10.1093/jjco/hys056. Epub 2012 Apr 21.
7
Gastrointestinal stromal tumor (GIST) and imatinib.
Int J Clin Oncol. 2006 Jun;11(3):184-9. doi: 10.1007/s10147-006-0579-0.
8
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1.
9
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Clin Cancer Res. 2017 Jan 1;23(1):171-180. doi: 10.1158/1078-0432.CCR-16-0529. Epub 2016 Jul 1.
10
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
Mol Cancer Ther. 2009 Aug;8(8):2172-82. doi: 10.1158/1535-7163.MCT-09-0193. Epub 2009 Aug 11.
引用本文的文献
1
Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.
Cancer Med. 2022 Oct;11 Suppl 1(Suppl 1):26-32. doi: 10.1002/cam4.5107.
2
Significance of Primary Malignant Tumors on the Outcome of Patients With Resected Gastrointestinal Stromal Tumors.
In Vivo. 2020 May-Jun;34(3):1201-1205. doi: 10.21873/invivo.11893.
3
Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia.
World J Gastroenterol. 2019 Aug 14;25(30):4261-4277. doi: 10.3748/wjg.v25.i30.4261.
4
The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies.
J Gastrointest Cancer. 2015 Dec;46(4):408-12. doi: 10.1007/s12029-015-9759-3.
5
Criminal or bystander: imatinib and second primary malignancy in GIST patients.
Chin J Cancer Res. 2013 Oct;25(5):490-2. doi: 10.3978/j.issn.1000-9604.2013.10.15.
本文引用的文献
1
Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
Jpn J Clin Oncol. 2012 Jul;42(7):578-85. doi: 10.1093/jjco/hys056. Epub 2012 Apr 21.
2
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Blood. 2011 Oct 20;118(16):4353-8. doi: 10.1182/blood-2011-06-362889. Epub 2011 Aug 16.
3
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
J Clin Oncol. 2011 Jul 20;29(21):2904-9. doi: 10.1200/JCO.2010.33.9275. Epub 2011 Jun 20.
4
KIT as a therapeutic target in metastatic melanoma.
JAMA. 2011 Jun 8;305(22):2327-34. doi: 10.1001/jama.2011.746.
5
Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2194-201. doi: 10.1158/1055-9965.EPI-08-0237.
6
Occurrence of other malignancies in patients with gastrointestinal stromal tumors.
Semin Diagn Pathol. 2006 May;23(2):120-9. doi: 10.1053/j.semdp.2006.09.004.
7
Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
J Am Coll Surg. 2006 Apr;202(4):623-9. doi: 10.1016/j.jamcollsurg.2006.01.002.
8
Small gastrointestinal stromal tumor concomitant with early gastric cancer: a case report.
World J Gastroenterol. 2006 Feb 7;12(5):815-7. doi: 10.3748/wjg.v12.i5.815.
9
Synchronous primary adenocarcinoma, mucosa-associated lymphoid tissue lymphoma and a stromal tumor in a Helicobacter pylori-infected stomach.
J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6. doi: 10.1046/j.1440-1746.2002.02649.x.
10
ARG tyrosine kinase activity is inhibited by STI571.
Blood. 2001 Apr 15;97(8):2440-8. doi: 10.1182/blood.v97.8.2440.
Zotero 插件